32 Acquisition International - Research & Development Awards 2022 FeNO testing is a cutting-edge procedure. The challenge is to spread the word so as many patients as possible can benefit. Routine asthma diagnosis and management were severely disrupted during the COVID-19 pandemic so we’re working hard to support customers as they resume FeNO testing. FeNO is gaining recognition as the most convenient biomarker in asthma diagnosis and we are happy to play our part in raising awareness of all the available options. COVID-19 stopped the face-to-face physician education that was helping us do this but we responded by moving our interactive training resources online with a series of free masterclasses, directed by our lead nurse and FeNO expert. Each session offers more detailed insight into asthma and FeNO testing, as well as the chance to ask questions and see firsthand how NIOX VERO® works. We have been delighted with the response, having welcomed attendees from all over the world. The masterclasses continue and are being renewed in 2022-23. More than 40 million FeNO tests have been performed worldwide using NIOX® technology, a great marker of success. Our 340 Million Reasons campaign, highlighting the need to keep using FeNO to help the global asthma population, was warmly received. We have also launched an innovative new website for patients: fenoandasthma.com. To keep up-to-date, subscribe to our newsletter at niox.com/subscribe. Of course, NIOX® will continue to evolve and we will strive to maintain our position on the frontline of R&D. Company: NIOX Group plc Name: Jonathan Emms, COO Email: info@circassia.com Web Address: www.niox.com Address: NIOX Group plc Hayakawa Building The Oxford Science Park Oxford, OX4 4GB, UK Telephone: +44 (0)1865 405560 Acquisition International R&D Awards 2022: IOX® is a medical device company dedicated to improving the lives of millions of people suffering from asthma. We do this by helping physicians assess patients more accurately using our proprietary NIOX® technology. NIOX® measures the level of fractional exhaled nitric oxide (FeNO) in the breath, with results proven to help in the diagnosis and management of asthma. We are proud to receive the award for Leaders in FeNO Testing Technology Development 2022. The accolade marks our commitment to leading research and development in FeNO testing and our continued support for the asthma and respiratory disease community. NIOX VERO® is the leading point-of-care FeNO monitoring and measurement device. When you consider how it all began, it really makes for a fascinating story. First came the discovery of the importance of nitric oxide as a signalling molecule in the body – so much so that work in the field received the Nobel Prize in Physiology or Medicine in 1998. This was followed by the discovery of the significance of FeNO as a biomarker in asthma and the development of NIOX® technology at the Karolinska Institute in Sweden. The ground-breaking innovations we’re able to develop now all started there. Sold in over 50 countries, NIOX VERO® is the only FeNO device simultaneously to hold a CE Mark and to be approved by the US FDA, China FDA (now the National Medical Products Administration) and NICE. We remain committed to that position. NIOX VERO® is also the only FeNO device fully compliant with recommendations from the American Thoracic Society and European Respiratory Society for the standardisation of FeNO measurement. This is thanks to the breathing handle that filters out nitric oxide in ambient air and organic compounds to ensure exhaled air is not contaminated, which could pose a risk to the accuracy of the result. In addition, NIOX VERO® features a unique Flow Rate Control™ mechanism to ensure the patient maintains a steady exhalation, further contributing to accuracy. The device also offers visual and audio guides to help patients complete the test. NIOX® technology has always been at the forefront of development. The technology was the first to deploy chemiluminescence in FeNO testing. The NIOX® electrochemical sensor was subsequently developed, allowing us to take the first portable FeNO device to market. Bringing FeNO testing out of the lab to the point-of-care was a significant breakthrough, not just for NIOX® but for FeNO as a biomarker in asthma management. Many more patients have benefited from the introduction of our point-of-care device and it’s an advance we were very proud to lead. Since then, NIOX VERO® has been selected by NICE to be part of the UK NHS Accelerated Access Collaborative (AAC). AAC works with innovators to streamline and accelerate the adoption of the best new products in healthcare. N Aug22514 NIOX® - Leaders in FeNO Testing Technology Development 2022
RkJQdWJsaXNoZXIy MTUyMDQwMA==